anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Clear cell renal cell carcinoma (ccRCC), the most common subtype of renal cell carcinoma, often leads to a poor prognosis due to metastasis. The investigation of N6-methyladenosine (m6A) methylation, a crucial RNA modification, and its role in ccRCC, particularly through the m6A reader insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2), revealed significant insights. We found that IGF2BP2 was notably downregulated in ccRCC, which correlated with tumor aggressiveness and poor prognosis. Thus, IGFBP2 has emerged as an independent prognostic factor of ccRCC. Moreover, a strong positive correlation was observed between the expression of IGF2BP2 and Netrin-4. Netrin-4 was also downregulated in ccRCC, and its lower levels were associated with increased malignancy and poor prognosis. Overexpression of IGF2BP2 and Netrin-4 suppressed the invasion and migration of ccRCC cells, while Netrin-4 knockdown reversed these effects in ccRCC cell lines. RNA immunoprecipitation (RIP)-quantitative polymerase chain reaction validated the robust enrichment of Netrin-4 mRNA in anti-IGF2BP2 antibody immunoprecipitates. MeRlP showed significantly increased Netrin4 m6A levels after lGF2BP2 overexpression. Moreover, we found that IGF2BP2 recognized and bound to the m6A site within the coding sequence of Netrin-4, enhancing its mRNA stability. Collectively, these results showed that IGF2BP2 plays a suppressive role in the invasion and migration of ccRCC cells by targeting Netrin-4 in an m6A-dependent manner. These findings underscore the potential of IGF2BP2/Netrin-4 as a promising prognostic biomarker and therapeutic target in patients with ccRCC metastasis.
The invention discloses a natural antimicrobial peptide Alligatorin4 and an application thereof in the antimicrobial aspect. The antimicrobial peptide Alligatorin4 disclosed by the invention is derived from Alligator sinensis. The mature peptide sequence of the antimicrobial peptide is obtained by retrieving a gene database of the Alligator sinensis, screening and analyzing, and the amino acid sequence is as shown in SEQ ID NO. 1 in a sequence table. By comparative analysis, the natural antimicrobial peptide Alligatorin4 is obviously different from the amino acid sequences of all the existing antimicrobial peptides, and belongs to a novel antimicrobial peptide. Antimicrobial experimental results show that the antimicrobial peptide Alligatorin4 disclosed by the invention has very strong antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria and fungi, has broad-spectrum and efficient antimicrobial effect, has the characteristics of low hemolytic activity, good salt tolerance, good heat tolerance, good heat stability and the like, and can be applied in preparation of medicines for resisting bacteria and inhibiting the growth of bacteria, preservatives, veterinary medicines, animal feeds and cosmetics.
The invention discloses a Chinese herb composition used for treating hyperostosis and a preparation method thereof. The Chinese herb composition is prepared from eggs and a Chinese herb composition body. The Chinese herb composition body is prepared from nepeta cataria, ligusticum wallichii, achyranthes aspera, radix angelicae and animal bone powder. The preparation method includes the steps that the nepeta cataria, ligusticum wallichii, achyranthes aspera and radix angelicae are weighed, then smashed by a pulverizer and finally mixed with the animal bone powder evenly to obtain herb powder of the Chinese herb composition body; the eggs are taken, an appropriate amount of egg white is poured out after holes are formed in the eggs through beating, and then the herb powder of the Chinese herb composition body is placed into the eggs; then, the eggs are placed into a pot to be steamed. The Chinese herb composition has the advantages of taking effect rapidly and being short in treatment course, good in treatment effect, low in cost, easy to prepare and small in toxic and side effect, relapse is not likely to occur, and the Chinese herb composition has the functions of expelling wind and removing cold, achieving dehumidification, activating blood to dissipate stasis, stimulating the circulation of blood and causing the muscles and joints to relax, softening a spur, easing pain and eliminating inflammations. Clinical tests prove that the average effective rate of the Chinese herb composition reaches 98%, the average effectual rate reaches 80%, and the average curing rate reaches 86.8%.
INTRODUCTION: Coughing during extubation can lead to several postoperative complications, including surgical site bleeding, intracranial hypertension and high intraocular pressure. Currently, various pharmacological and non-pharmacological interventions are employed in clinical practice to reduce coughing during extubation. However, it is unclear which of these interventions has the best preventive effect and the fewest adverse events. Therefore, we plan to conduct a systematic review and network meta-analysis to compare the effects of all interventions.
METHODS AND ANALYSIS: We will search MEDLINE, Embase, Web of Science, Cochrane Central Register of Controlled Trials, CNKI and Wanfang databases, as well as reference lists from previously published papers, from the date of their inception to April 2024. We will only include randomised controlled trials, regardless of publication in any language. The primary outcome is the incidence of cough during extubation, using the modified Minogue scales. The secondary outcomes are as follows: (1) the incidence of severe coughing (grade 4); (2) the incidence of other types of postoperative airway complications, such as laryngospasm, apnoea, hypoxaemia and sore throat, which will be evaluated within 24 hours after surgery; (3) the side effects related to the interventions, such as bradycardia (heart rate less than 60 beats per minute), hypotension or allergic reactions, which will be evaluated within 24 hours from the start of the drug to the postoperative period and (4) the time from the end of the surgery to the extubation of the endotracheal tube. The articles meeting the criteria will be independently evaluated by two researchers based on the established screening criteria. The data will then be extracted. Bias will be assessed for all included studies using the Cochrane Risk of Bias Risk Assessment Tool Version 2. We will use the Netmeta package of the R software with a random-effects model to make direct and indirect comparisons through the frequency framework. We will assess the quality of evidence using Confidence in Network Meta-Analysis.
ETHICS AND DISSEMINATION: Ethical approval is not required for this protocol, as we will only pool published data. We plan to submit our manuscript for publication in a peer-reviewed academic journal.
PROSPERO REGISTRATION NUMBER: CRD42023401609.
Breast cancer patients from the IPPT Breast Clinic who meet the inclusion criteria will be contacted and informed about the study and procedure. Informed consent will be obtained once the respondent agrees to participate. In the case of group psychological intervention, 8 breast cancer patients form one group, and group psychological intervention is given once a week for four weeks as part of the treatment process. The batteries of assessment were carried out at 3-time points; pre-intervention, post-intervention, and 3 months after the intervention.
Disseminated fungal infections are a leading cause of mortality in children who receive hematopoietic stem cell transplantation (SCT). Therefore, children routinely receive prophylactic and empirical antifungal therapy after SCT. The most commonly used antifungal agent in this population is voriconazole. Voriconazole can be given via intravenous or oral routes and children who are post SCT are routinely switched from the intravenous to oral formulation at the time of hospital discharge. However, the absorption and systemic exposure of oral voriconazole has not been well-described in children. Furthermore, many children who undergo transplantation develop gastrointestinal graft versus host disease and this likely impacts oral absorption. The magnitude of effect resulting from graft versus host disease on absorption of voriconazole and subsequent blood concentrations in children is unknown. Thus children with graft versus host disease are at a particularly high risk of inadequate absorption with subsequent sub-therapeutic levels of voriconazole. They may need higher or more frequent dosing to achieve therapeutic levels. The purpose of my research project is to define the pharmacokinetics of oral voriconazole and establish dosing guidelines in children following SCT.
Patients with low and selected intermediate risk prostate cancer are treated with prostate HDR brachytherapy as monotherapy. The prescribed dose is 1x19 Gy to the whole prostate. Ir-192 radioactive source is used. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time dose optimization is applied.
Participants will complete three 30-minute bouts of semi-recumbent cycling at incrementally increasing fixed metabolic heat loads (150, 200 and 250 W/m2) in a hot, dry condition (40°C, 15% relative humidity). Each exercise bout will be separated by a 15 minute period of rest, with the final recovery 1 hour in duration. Exercise will commence between the hours of 7 AM and 9 AM following a period of normal sleep (\~8 hours) (Control condition).
The invention relates to a sulfonamides compound for inhibiting carbonic anhydrase II and a synthesis method and an application thereof. The compound has the structure as shown in the specification. The invention features economical and reasonable synthetic route and high utilization of resources. The synthesis method is simple and easy to carry out and is more suitable for large-scale industrialized production. With human carbonic anhydrase II (Human Carbonic Anhydrase II, hCA II) expressed by procaryotic cell as an enzyme source, the invention establishes an in-vitro carbonic anhydrase inhibitor screening model. In addition, the compound of the invention has inhibitive effect on activity of the human carbonic anhydrase II.
The study intervention consists of a tablet-based cognitive training, targeting the cognitive domains mostly affected by AD. This training will be performed for three months (each day for 20 minutes). After three months this group will continue the training at home for six months and meet monthly for group sessions (i.e. booster sessions) on site.
The present invention relates to application of L-threonic acid, and a derivative of L-threonic acid, or salt of L-threonic acid (except L-threonic acid calcium and heavy metal salt) for preparing medicine for preventing and treating osteoporosis. Animal experiments prove that when threonic acid sodium is continuously used for 10 weeks, the threonic acid sodium has the good function of improving various pathological data of osteoporosis, and the bone density of the thighbone of a rat can be obviously enhanced (compared with p before administration, p is less than 0.01). Compared with the bone density of the thighbone and the calcium content of bone in a model control group, the bone density of the thighbone and the calcium content of bone of the rat can be obviously increased. Compared with the density and the thickness of bone trabecula in the model control group, the density and the thickness of bone trabecula can be increased. Compared with the content of ur-pyridinium before administration, the content (which is p of less than 0.01) of ur-pyridinium after the administration can be obviously reduced. Compared with the content of ur-calcium before administration, the content (which is p of less than 0.05) of ur-calcium can be obviously reduced.
OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of MEN-10755 in patients with recurrent or refractory adult solid tumors. II. Determine the qualitative and quantitative toxic effects of MEN-10755 and study the predictability, duration, intensity, onset, reversibility, and dose relationship of the toxic effects in these patients. III. Propose a safe dose for phase II study. IV. Assess the pharmacokinetics of MEN-10755 at different dose levels in these patients. V. Document any possible antitumor activity of MEN-10755.

OUTLINE: This is an open label, nonrandomized study. Patients receive MEN-10755 as a single 15 minute intravenous infusion every 3 weeks, or upon recovery from toxicity. Doses will be escalated in decreasing rates and depending on the clinical judgement of the investigator. The MTD is the dose at which dose limiting toxicity is observed in at least 2 of 6 patients at a given dose level. Patients will be removed from the study if cardiac toxicity, disease progression, or renal, cardiac or pulmonary decline is present.

PROJECTED ACCRUAL: At least 5 evaluable patients will be enrolled.
BACKGROUND: Triple-negative breast cancer (TNBC) is a subtype of breast cancer with a poor prognosis, and the outcomes of common therapy were not favorable.
METHODS: The samples of 84 patients with TNBC and 40 patients with breast fibroadenoma were collected in the pathology department specimen library of our hospital. The prognosis of patients was obtained through outpatient follow-up information, telephone and WeChat contacts, and medical records. The mRNA expression was analyzed using bioinformation and quantitative real-time polymerase chain reaction (qPCR). The protein expression was determined by hematoxylin-eosin staining and immunohistochemical staining. The results of survival analysis were visualized using Kaplan-Meier curves.
RESULTS: The immunohistochemical staining showed that hypoxia-inducible factor-1alpha (HIF-1α) was mainly distributed in the nucleus and cytoplasm, while CD147 is mainly distributed in cell membrane and cytoplasm. The qPCR results exhibited that the expression level of HIF-1α and CD147 in TNBC tissue was significantly higher than that in breast fibroadenoma tissue. The expression of HIF-1α was related to the histological grade and lymph node metastasis in TNBC, and the expression of CD147 was related to Ki-67, histological grade and lymph node metastasis. There was a positive relationship between the expression of CD147 and HIF-1α. The upregulated expression of CD147 was closely related to the poor prognosis of OS in TNBC.
CONCLUSION: CD147 could be a biomarker for the prognosis of TNBC and closely related to the expression of HIF-1α.
OBJECTIVE: To analyze the association of food insecurity (FI) with chronic noncommunicable diseases (NCDs) in the Brazilian context.
METHODS: The review protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO). The searches were conducted in LILACS and PubMed databases (September/2022). Observational studies carried out in the Brazilian population published since 2003 were included, in which: (1) the association of FI with NCDs was analyzed; and (2) the Brazilian Food Insecurity Scale was used. Studies on pregnant women and those that associated FI with cancer, sexually transmitted infections, and musculoskeletal and respiratory diseases were excluded. The studies were subjected to methodological quality assessment.
RESULTS: A total of 27 cross-sectional studies were included; nine used secondary data from national surveys, and the others used primary data. An association between FI and overweight and obesity in different age groups was verified in the studies.
CONCLUSION: The included articles did not produce evidence on other NCDs of interest to health in Brazil such as diabetes and high blood pressure. However, they corroborate the already-known relationship between obesity and FI. Studies on the topic, with a longitudinal design, should be encouraged.
Objective To clarify the relationship between astrocyte activation patterns and disease progression in epidemic encephalitis B (Japanese encephalitis). Methods First, a mouse model of epidemic encephalitis B was constructed by foot-pad injection of Japanese encephalitis virus (JEV), and the expression of viral protein NS3 in different brain regions was detected by immunofluorescence assay (IFA). Next, IFA, RNA sequencing (RNA-seq) and real-time quantitative PCR (qRT-PCR) were used to clarify the changes in the astrocyte activation patterns at different stages of epidemic encephalitis B. Finally, intracerebroventricular administration of irisin was conducted to regulate the proportion of activation in complement C3-positive A1 astrocytes and S100A10-positive A2 astrocytes, investigating whether it could improve the body mass, behavioral scores, and brain tissue damage in a mouse model. Results NS3 protein was detected by IFA predominantly in the M1/M2 region of the motor cortex and the hippocampus. The number and volume of GFAP-positive astrocytes significantly increased in JEV-infected brain regions, in which the expression of multiple genes associated with A1/A2 astrocyte activation was significantly enhanced. Although intracerebroventricular or intraperitoneal injection of irisin did not improve the prognosis of epidemic encephalitis B, it inhibited the activation of A1 astrocytes and ameliorate neuroinflammation. Conclusion Neurons in the M1/M2 motor cortex and hippocampus are susceptible to JEV infection, in which the abnormal astrocyte activation contributes to the neuroinflammatory injury. Irisin administration may restrain A1 astrocyte activation and alleviate neuroinflammation following JEV infection.
This invention relates to the field of medicine, in particular, to endocrinology. This invention offers a method of potentiation of a therapeutic effect of exenatide by administration of an effective quantity of exenatide in combination with an effective quantity of dalargin. Advantageous therapeutic effects of the invention include lowering of pathologically elevated levels of blood glucose and cholesterol in patients suffering from diabetes mellitus. This invention offers a method of treatment of diabetes mellitus by administration of an effective quantity of exenatide in combination with an effective quantity of dalargin. This invention offers the use of the combination of exenatide and dalargin for the preparation of the medication for the treatment of diabetes mellitus. This invention offers a medicinal preparation for the treatment of diabetes mellitus containing an effective quantity of exenatide, an effective quantity of dalargin and a pharmaceutically acceptable vehicle or diluent, as well as a method of preparation of this preparation. This invention offers a medicinal preparation for the treatment of diabetes mellitus in the form of a kit containing the medicinal preparation exenatide and the medicinal preparation dalargin, as well as a method of use of this medicinal preparation.
Although gut dysbiosis is associated with cow's milk allergy (CMA), causality remains uncertain. This study aimed to identify specific bacterial signatures that influence the development and outcome of the disease. We also investigated the effect of hypoallergenic formula (HF) consumption on the gut microbiome of milk-allergic children. 16S rRNA amplicon sequencing was applied to characterize the gut microbiome of 32 milk-allergic children aged 5-12 years and 36 age-matched healthy controls. We showed that the gut microbiome of children with CMA differed significantly from that of healthy children, regardless of whether they consumed cow's milk. Compared to that of healthy cow's milk consumers, it was depleted in Bifidobacterium, Coprococcus catus, Monoglobus, and Lachnospiraceae GCA-900066575, while being enriched in Oscillibacter valericigenes, Negativibacillus massiliensis, and three genera of the Ruminococcaceae family. Of these, only the Ruminococcaceae taxa were also enriched in healthy children not consuming cow's milk. Furthermore, the gut microbiome of children who developed tolerance and had received an HF was similar to that of healthy children, whereas that of children who had not received an HF was significantly different. Our results demonstrate that specific gut microbiome signatures are associated with CMA, which differ from those of dietary milk elimination. Moreover, HF consumption affects the gut microbiome of children who develop tolerance.
The Paleolithic lifestyle (PL) intervention during radiotherapy consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed. Patients were supposed to start the PL intervention at least two days prior to the first irradiation and to protocol their food consumption on two days during the first week on the diet. They were also asked about their compliance to the PL intervention at each weekly measurement appointment.
The present invention relates to the composition of nanometer SOD and ginseng or the extract of ginseng, and a preparation method of the composition. In 1 to 100000 active units of nanometer SOD, 1 to 50 g of nanometer ginseng or the extract of nanometer ginseng is contained, and the grain diameter is smaller than or equal to 10 to 80 nanometers. The combination application of the nanometer composition of the nanometer SOD and the ginseng or the extract of the ginseng enhances the concentration and the effective components of the drug. The anti-oxidation activity is enhanced by more than 10 times, the skin and mucous membrane absorptivity reaches more than 98%, and the half-life is prolonged by more than two orders of magnitude. The composition of nanometer SOD and ginseng or the extract of ginseng can enter cells to directly clear free radicals, and has stronger anti-lipid peroxidation. The comprehensive drug effects are more thoroughly exerted and are much better than the drug effects of the traditional compound Chinese drugs. The composition of nanometer SOD and ginseng or the extract of ginseng is used for first aid and for treating diseases of cardiovascular systems, diseases of the stomach and the liver, diabetes, psychopathy, neurasthenia and impotence. Ginseng contains rich SOD, and is suitable for athletes, emergent patients, and people with external wounds. The absorption speed is high. The drug effect of the composition of nanometer SOD and ginseng or the extract of ginseng is 3 to 5 times higher than that of SOD, and is 5 to 10 times higher than that of ginseng. The composition of nanometer SOD and ginseng or the extract of ginseng is contribution to the human medicine career.
C3 (Metformin, Simvastatin and Digoxin) will be dosed each day of a 28 calendar day cycle. The starting dose level will be increased with each cohort. There are 3 cohorts. Upon reaching maximum tolerated dose, an expansion cohort will be opened. Cohort 1 - Metformin 850mg po/day, Simvastatin 5mg po/day, Digoxin 0.0625 mg po/day. Cohort 2 - Metformin 850 mg po/day for two weeks and 1,700 mg po/day for next two weeks, Simvastatin 20 mg po/day, Digoxin 0.25 mg po/day. Cohort 3 - Metformin 850 mg po/day for two weeks and 1,700 mg po/day for next two weeks, Simvastatin 40 mg po/day, Digoxin 0.25 mg po/day for two weeks, 0.375 mg po/day for the next two weeks for cycle 1. Subjects will receive 0.50 mg po/day in Cohort 3, Cycle 2 and beyond. Metformin to be taken at Breakfast and Dinner time (as applicable), Simvastatin at Bed time and Digoxin once daily.